Our
people
Professor Adam Nelson
Title
Professor of Chemical Biology
A.S.Nelson@leeds.ac.uk
Phone
0113 3436502
BHRC Role
Deputy director of the MCCB Technology Group
Research Interests
- Synthesis of biologically active compounds
- Diversity-oriented synthesis
- Chemical Genetics
- Chemical Biology
- Directed evolution of enzymes for use in organic synthesis
About
Adam Nelson is Professor of Chemical Biology at the University of Leeds, with research interests in synthetic organic chemistry and chemical biology. He obtained a BA in Natural Sciences from Churchill College, University of Cambridge in 1993, and his PhD (under the supervisor of Dr Stuart Warren) in Synthetic Organic Chemistry, also from Cambridge, in 1996. He undertook postdoctoral research with Prof. E. J. Thomas at the University of Manchester before joining the academic staff at the University of Leeds in 1998.
Professor Nelson is Director of the Astbury Centre for Structural Molecular Biology, an identified University Centre of Excellence within the University of Leeds, and holds a EPSRC Advanced Research Fellowship (2004-2009) to develop his research in Chemical Genetics.
Professor Nelson was awarded the RSC Meldola medal (2001), a Pfizer Academic Award (2002), an AstraZeneca Research award in Organic Chemistry (2005) and an RSC Corday-Morgan medal (2007).
Professor Nelson’s research group are interested in synthetic organic chemistry and its application to biological problems. They focus on the development of new strategies and methods for asymmetric and stereoselective synthesis, which they apply in the synthesis of biologically active molecules and natural products.
Synthesis is an immensely powerful tool in Chemical Biology, which theyexploit in a wide range of applications; from the evolution of new enzymes for synthetic chemistry, to the discovery of new modulators of protein function.
Grants Awarded
Current and recent research has been funded by EPSRC, BBSRC, the Wellcome Trust, the Leverhulme Trust, the Royal Society, the Nuffield Foundation and industry (Aventis, Pfizer, Syngenta, AstraZeneca, GlaxoSmithKline, Avecia, F. Hoffmann-La Roche and Organon).
Related Links
